- Home
- HPQ vs ARGX Comparison
HPQ vs ARGX Comparison
Compare HPQ & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPQ
- ARGX
- Stock Information
- Founded
- HPQ 1939
- ARGX 2008
- Country
- HPQ United States
- ARGX Netherlands
- Employees
- HPQ N/A
- ARGX N/A
- Industry
- HPQ Computer Manufacturing
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HPQ Technology
- ARGX Health Care
- Exchange
- HPQ Nasdaq
- ARGX Nasdaq
- Market Cap
- HPQ 35.5B
- ARGX 35.2B
- IPO Year
- HPQ N/A
- ARGX 2017
- Fundamental
- Price
- HPQ $36.79
- ARGX $606.47
- Analyst Decision
- HPQ Hold
- ARGX Strong Buy
- Analyst Count
- HPQ 11
- ARGX 21
- Target Price
- HPQ $36.77
- ARGX $619.79
- AVG Volume (30 Days)
- HPQ 8.4M
- ARGX 314.5K
- Earning Date
- HPQ 11-26-2024
- ARGX 10-31-2024
- Dividend Yield
- HPQ 3.00%
- ARGX N/A
- EPS Growth
- HPQ N/A
- ARGX N/A
- EPS
- HPQ 2.81
- ARGX N/A
- Revenue
- HPQ $53,559,000,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- HPQ $4.22
- ARGX $61.99
- Revenue Next Year
- HPQ $3.17
- ARGX $42.48
- P/E Ratio
- HPQ $13.09
- ARGX N/A
- Revenue Growth
- HPQ N/A
- ARGX 85.56
- 52 Week Low
- HPQ $27.43
- ARGX $327.73
- 52 Week High
- HPQ $39.80
- ARGX $622.32
- Technical
- Relative Strength Index (RSI)
- HPQ 49.72
- ARGX 59.06
- Support Level
- HPQ $33.53
- ARGX $601.64
- Resistance Level
- HPQ $39.80
- ARGX $622.32
- Average True Range (ATR)
- HPQ 1.14
- ARGX 11.91
- MACD
- HPQ -0.16
- ARGX 0.77
- Stochastic Oscillator
- HPQ 51.99
- ARGX 75.30
About HPQ HP Inc.
HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.